1-3 of 3
Randi Nygaard
Close
Sort by
Journal Articles

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

Clinical Trials & Observations
Kjeld Schmiegelow, Ibrahim Al-Modhwahi, Mette Klarskov Andersen, Mikael Behrendtz, Erik Forestier, Henrik Hasle, Mats Heyman, Jon Kristinsson, Jacob Nersting, Randi Nygaard, Anne Louise Svendsen, Kim Vettenranta, Richard Weinshilboum
Journal: Blood
Blood (2009) 113 (24): 6077–6084.
https://doi.org/10.1182/blood-2008-11-187880
Published: 2009
Journal Articles

Response: Could mutations in the hypoxanthine-guanine phosphoribosyl transferase gene induced by thiopurine therapy promote the development of second malignant neoplasms?

Kjeld Schmiegelow, Ibrahim Al-Modhawi, Mette Klarskov Andersen, Mikael Berendtz, Erik Forestier, Henrik Hasle, Mats Heyman, Jon Kristinsson, Jacob Nersting, Randi Nygaard, Anne Louise Svendsen, Kim Vettenranta, Richard Weinshilboum
Journal: Blood
Blood (2009) 113 (24): 6258–6259.
https://doi.org/10.1182/blood-2009-03-210195
Published: 2009
Journal Articles

Risk of Second Malignant Neoplasm Is Related to TPMT Activity and Duration of MTX/6MP Maintenance Therapy of ALL.

Kjeld Schmiegelow, MD, Ibrahim Al-Modhawi, M.D., Mikael Berendtz, M.D., Erik Forestier, M.D., Henrik Hasle, M.D., Mats Heyman, M.D., Jon Kristinsson, M.D., Randi Nygaard, M.D., Kim Vettenranta, M.D.
Journal: Blood
Blood (2006) 108 (11): 1853.
https://doi.org/10.1182/blood.V108.11.1853.1853
Published: 2006